Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker

Cancer Biology and Therapy

Volumn 11, Issue 6, 2011, Pages 552-558

  Dewar, Rajan ^a   Chen, Sing Tsung ^b   Yeckes Rodin, Heather ^c   Miller, Kenneth ^d   Khosravi Far, Roya ^a,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Clarient Diagnostic Services   (United States)

^c Hematology Oncology Associates   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BCR ABL; Bortezomib; Philadelphia positive precursor B acute lymphoblastic leukemia (Ph+ALL); Proteasomal inhibition

Indexed keywords

BCR ABL PROTEIN; BIOLOGICAL MARKER; BORTEZOMIB; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; CELL TRANSFORMATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; LEUKEMOGENESIS; MALE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; FUSION PROTEINS, BCR-ABL; HUMANS; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRAZINES; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79952767864     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.6.14675     Document Type: Article

References (17)

1. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci USA 2003; 100:6523-8. (Pubitemid 36666614)
2. Jagani Z, Singh A, Khosravi-Far R. FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta 2008; 1785:63-84. (Pubitemid 350192084)
3. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109:3189-97. (Pubitemid 46572503)
4. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110:2309-15. (Pubitemid 47523149)
5. Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Duhrsen U, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007; 109:2068-76. (Pubitemid 46745234)
6. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103:4396-407. (Pubitemid 38745962)
7. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007; 109:3676-8. (Pubitemid 46641715)
8. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24:4867-74. (Pubitemid 46655613)
9. Jagani Z, Song K, Kutok JL, Dewar MR, Melet A, Santos T, et al. Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res 2009; 69:6546-55.
10. Wiberg K, Carlson K, Aleskog A, Larsson R, Nygren P, Lindhagen E. In vitro activity of bortezomib in cultures of patient tumour cells - potential utility in haematological malignancies. Med Oncol 2009; 26:193-201.
11. + cells sensitive and resistant to STI571. Blood 2003; 102:3765-74.
12. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abldependent and -independent mechanisms. Blood 2004; 104:509-18. (Pubitemid 38900035)
13. Song K, Mariappan R, Khosravi-Far R. Analysis of TNF-related apoptosis-inducing ligand in vivo through bone marrow transduction and transplantation. Methods Enzymol 2008; 446:315-31.
14. Gu TL, Tothova Z, Scheijen B, Griffin JD, Gilliland DG, Sternberg DW. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood 2004; 103:4622-9. (Pubitemid 38745994)
15. Jonsson M, Engstrom M, Jonsson JI. FLT3 ligand regulates apoptosis through AKT-dependent inactivation of transcription factor FoxO3. Biochem Biophys Res Commun 2004; 318:899-903. (Pubitemid 38625858)
16. Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002; 277:47928-37. (Pubitemid 36159321)
17. Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer 2010; 55:254-9.